07.03.2025 • News

Rio Tinto Completes Acquisition of Arcadium Lithium

Rio Tinto has completed the $6.7 billion acquisition of Arcadium Lithium and is now the parent company of Arcadium Lithium, which will be renamed Rio Tinto Lithium and will also include the Rincon Lithium Project.

The deal establishes Rio Tinto as a global leader in the supply of energy transition materials and as a major lithium producer, with one of the world’s largest lithium resource bases, the company said. Rio Tinto Lithium aims to grow the capacity of its assets to over 200,000 t/y of lithium carbonate equivalent (LCE) by 2028.

Rio Tinto CEO Jakob Stausholm said: “Together, we are accelerating our efforts to source, mine and produce minerals needed for the energy transition. By combining Rio Tinto’s scale, financial strength, operational and project development experience with Arcadium’s Tier 1 assets, technical and commercial capabilities, we are creating a world-class lithium business which sits alongside our leading iron ore, aluminium and copper operations.”

“We believe we are well-positioned to deliver the materials needed for the energy transition while maintaining our focus on respecting local communities, minimizing environmental impacts and delivering value for shareholders and other stakeholders,” Stausholm added.

Arcadium Lithium shareholders will receive total cash consideration of $5.85 for each share.

© jroballo – stock.adobe.com
© jroballo – stock.adobe.com

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read